RXi Pharmaceuticals: Extreme Volatility Attracts Traders, But Long-Term Worries Persist

Although RXi Pharmaceuticals burnt far less cash than expected, the company and management have given little in the way of anticipated 2018 plans or data reads which shareholders desperately need if this stock is to survive.